Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, peginterferon alfa-2a (Pegasys®) cannot be endorsed for use within NHS Wales for the treatment of HBeAg-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. |
||
|
||
Medicine details |
||
| Medicine name | peginterferon alfa-2a (Pegasys®) | |
| Formulation | 135 micrograms solution for injection, 180 micrograms solution for injection, 90 micrograms solution for injection | |
| Reference number | 2028 | |
| Indication | For the treatment of HBeAg-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. |
|
| Company | Roche Products Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 05/03/2018 | |
| Date of issue | 06/03/2018 | |